by Mark Curtis | Apr 7, 2015
. Welcome to your Update from the Clinic for the month of March. Investors weren’t so keen on Neuralstem’s topline results in amyotropic lateral sclerosis (ALS). NeoStem’s follow-up data from its PreSERVE study in acute myocardial infarction (AMI) was somewhat...
by Stacey Johnson | Apr 3, 2015
. Last month (March 13), StemCellTalks held a symposium on diabetes and stem cell tourism to educate Toronto high school students about the field. (These events happen across Canada.) The morning session began with Dr. Elia Piccinini (University of Toronto) giving an...
by Lisa Willemse | Mar 27, 2015
> This is my final post as co-editor of Signals, and in sitting down to draft it, I found myself struggling to find words. How do you sum up six years of blogging? Quite simply, you don’t. However, as this also marks the end of the Stem Cell Network’s involvement...
by Mark Curtis | Mar 25, 2015
. Welcome to your Update from the Clinic for the month of February. Northwest Biotherapeutics received approval from Health Canada to proceed with its ongoing Phase 3 clinical study in Glioblastoma multiforme at clinical sites in Quebec. Sangamo and bluebird bio both...
by David Kent | Mar 16, 2015
> The last 15 years of stem cell research have been full of hope and promises – some of it delivered upon, most of it not quite there yet, and some of it miserably failed. I guess that is to be expected in a highly experimental area of medicine, but one of the most...
by Nick Dragojlovic | Mar 4, 2015
> Scientists: I have some questions. Have you ever written a blog post about your field? Tweeted a link to a new scientific publication? Joined a forum discussion about the latest research? As it turns out, your likelihood of answering “yes” to one or more of these...
Comments